SCHEMBL13013116

SCHEMBL13013116

C/C(=N/CC/N=C(\C)c1ccccc1O)c1ccccc1O

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.65
MEN1 O00255 3/20 0.65
NPC1 O15118 1/20 0.65
ALDH1A1 P00352 4/20 0.49
RAB9A P51151 1/20 0.49
ALOX15 P16050 1/20 0.49
KDM4E B2RXH2 4/20 0.47
KDM1A O60341 1/20 0.44
HPGD P15428 2/20 0.43
LMNA P02545 2/20 0.42
ALPL P05186 1/20 0.42
NFKB1 P19838 1/20 0.42
NFKB2 Q00653 1/20 0.42
RELA Q04206 1/20 0.42
MAPT P10636 2/20 0.41
CCR6 P51684 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
CXCR5 P32302 1/20 0.41
APLNR P35414 1/20 0.41
LRRK2 Q5S007 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10609916 1.00 KMT2A (0.65) KMT2AMEN1NPC1ALDH1A1RAB9A
SCHEMBL12013645 1.00 KMT2A (0.65) KMT2AMEN1NPC1ALDH1A1RAB9A
SCHEMBL10609912 1.00 KMT2A (0.65) KMT2AMEN1NPC1ALDH1A1RAB9A
SCHEMBL17089330 0.90 KMT2A (0.59) KMT2AMEN1NPC1ALDH1A1RAB9A
SCHEMBL16627917 0.90 KMT2A (0.59) KMT2AMEN1NPC1ALDH1A1RAB9A
SCHEMBL13114661 0.88 KMT2A (0.57) KMT2AMEN1NPC1ALDH1A1RAB9A
SCHEMBL21368434 0.88 KMT2A (0.57) KMT2AMEN1NPC1ALDH1A1RAB9A
SCHEMBL17089328 0.88 KMT2A (0.57) KMT2AMEN1NPC1ALDH1A1RAB9A
SCHEMBL17089334 0.88 KMT2A (0.57) KMT2AMEN1NPC1ALDH1A1RAB9A
SCHEMBL21352277 0.87 KMT2A (0.55) KMT2AMEN1NPC1ALDH1A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9437828-B2 Electroluminescent device using azomethine-lithium-complex as electron injection layer MERCK PATENT GMBH (DE) 2016-09-06 US disclosed
US-9437828-B2 Electroluminescent device using azomethine-lithium-complex as electron injection layer MERCK PATENT GMBH (DE) 2016-09-06 US disclosed
US-20150065725-A1 ELECTROLUMINESCENT DEVICE USING AZOMETHINE-LITHIUM-COMPLEX AS ELECTRON INJECTION LAYER MERCK PATENT GMBH (DE) 2015-03-05 US disclosed
US-20150065725-A1 ELECTROLUMINESCENT DEVICE USING AZOMETHINE-LITHIUM-COMPLEX AS ELECTRON INJECTION LAYER MERCK PATENT GMBH (DE) 2015-03-05 US disclosed
US-20100327264-A1 ELECTROLUMINESCENT DEVICE USING AZOMETHINE-LITHIUM-COMPLEX AS ELECTRON INJECTION LAYER MERCK PATNET GMBH (DE) 2010-12-30 US disclosed
US-20100327264-A1 ELECTROLUMINESCENT DEVICE USING AZOMETHINE-LITHIUM-COMPLEX AS ELECTRON INJECTION LAYER MERCK PATNET GMBH (DE) 2010-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100327264-A1 ELECTROLUMINESCENT DEVICE USING AZOMETHINE-LITHIUM-COMPLEX AS ELECTRON INJECTION LAYER ACSL3, APOL1, INTS9 KMT2A 3016/4885MEN1 2888/4885NPC1 1206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.